Treatment of Acute Liver Failure in Suspected Acetaminophen (APAP) Hepatotoxicity

Acute liver failure presenting in the setting of suspected acetaminophen (APAP) hepatotoxicity represents a time-critical emergency. The cause-specific nature of this presentation allows for targeted early intervention — timing matters significantly.

Clinical Scenario

This protocol applies to patients with acute liver failure in the context of suspected acetaminophen (APAP) hepatotoxicity. Prompt identification of this etiology is essential because it directly determines the therapeutic approach.

Treatment Approach

Management centres on two early interventions: gastric decontamination when the ingestion is sufficiently recent, and administration of N-acetylcysteine (NAC) — the only effective antidote in this setting. Both the route and the timing of NAC administration are protocol-specific. Full dosing protocols, administration schedules, and decision criteria are detailed in the complete regimen →

Primary Clinical Goal

✓ Target recovery endpoint: improvement of INR to <1.5.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.14309/ajg.0000000000002340

In patients with suspected APAP toxicity, we recommend early administration of NAC.
Early gastric decontamination with 1-2 g/kg of single-dose activated charcoal is effective if administered within the first 4 hours after ingestion.
NAC is the only effective antidote for APAP hepatotoxicity.
The most commonly used end point is the improvement of INR to <1.5.

View source ↗